The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How the f.. is this at 0.7p in old money? I might be a little naive but for this to be so low following all of the progression is a joke and the BoD have a lot to answer for in my opinion. Shareholder value and confidence just doesn't seem to matter. It's just a token line we get fed whenever AGM is coming around. I'm sick to the back teeth of it.
If they raise over $50m they may appear in the link below it updates daily; https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-24
Late RF dump.
Jeeeezzz... I have just looked on HL, was this really down another 8.57% today?????
As the licencee is a Private company, is it correct to say they canβt do a conventional raise. Therefore are we looking at a company that will raise funds via a biotech crowdfunding platform? If so it might not be so difficult to identify them.
Would a pleasant surprise if after the funding milestone the next is a first dosage milestone or submitted application for trial hopefully this time with no territory component like before.
Amended terms of a 2016 licensing agreement between Sierra Oncology Inc and CRT Pioneer Fund LP (CPF) for SRA737.
The AIM-listed drug development firm said under the 2016 agreement SRA737 was licensed to Sierra by CPF for up to US$328.5mln in developmental, regulatory and commercial milestones, plus royalties on the net sales of any product successfully developed. Sareum was eligible to receive 27.5% of the economics equating to up to US$88mln in milestone payments, plus sales royalties, as SRA737 advanced.
Under the terms of the original agreement, additional payments of up to an aggregate of US$319.5mln were payable to CPF upon the achievement of certain milestones, including a milestone payment of US$7.5mln upon the dosing of the first patient in the first Phase 1 trial of SRA737 in the US, and a payment of US$12mln upon the dosing of the first patient of a randomised Phase 2 trial of SRA737.
Under the amended agreement, Sareum and CPF have agreed to a decrease in the additional milestone payments of up to US$290mln that may be payable to CPF upon the achievement of certain milestones, including a milestone payment of US$2mln upon the dosing of the first patient of the first trial of SRA737 following the amendment
Evening Leggster - yeah, as far as I can see the earliest milestone is simply dependent on accessing funding or even sub-licencing as the RNS refers to commercial objectives.
Thereafter the RNS stated, "Additional payments to the aggregate amount of up to US$289 million may become payable to CPF under the Licensing Agreement, subject to achievement of certain development, regulatory and commercial milestones." So this would probably include the payment clauses relating to getting 737 into patients that BenH alluded to.
Although I've previously suggested 737 might be back in the hands of Sierra, as they are now a GSK company I can't see how funding would be any sort of issue. I expect I'll continue to overthink things until the truth comes out.
HBD, I agree I think that first milestone being financial is helpful to SAR and IMO will probably be soon assuming the licencee moved to the raise quickly. What I wonder though is what the next milestones will be (or not) after that first step is reached. Are other milestone in the agreement trigger once a step is achieved.... GLA
Hi Ben - from the Jan 2nd RNS, "An additional fee made up of up to US$1.0 million cash and 500,000 shares in the Licensee Company (the "Consideration Shares") may be payable upon the sooner of 12 months following the signing of the Licensing Agreement, or the event of the Licensee Company achieving certain commercial and material financing objectives."
The above only talks about commercial & funding objectives rather than clinical progress which suggests the milestones may appear sooner rather than later since (I'd assume) funding needs to come before clinical trials start.
If I've interpreted this correctly, it might seem a bit odd as you'd expect a biotech company to be looking at clinical trials to indicate progress/success whereas the above maybe suggests that they have a different business model in mind, or CPF have recognised this approach could actually be better in the short term for CPF/SAR as the milestones will be based on funding rather than trial outcomes i.e. any trial would probably take longer to design/begin compared to arranging funding.
All just guesswork for now.
Am I right in thinking the first payment of a milestone will be 'first dosing' in a trial?
So presumably we will not get an RNS saying "Payment received for XYZ" until someone spots a clinical trial between a CHK1 inhibitor and gemcitabine etc...
I am heartened by the inability of a big pharma to hide all information about progress. We have some very eagle eyed spotters on here who know where to look and what to look for. I am grateful for their efforts.
Your logic on thus issue is sound HbD.
A waiting game until progression of 737 by the licencee.
Regards
Great to here from you C79
Interesting link below not far away from your zero inflated beta distribution.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080968/
Regards
Morning SOG - since we're only financial beneficiaries of the on-licence deal, there could be a totally watertight NDA that prevents CPF telling us who now has 737. Even if the BoD know who it is, they maybe aren't able to say anything until the licence holder makes an announcement.
Bleedin' frustrating, if you ask me.
Good morning C79,
Pleased to hear all is well.
I concur with your comments regarding the disruptors!
I agree also that good news seems to be imminent.
Looking forward to your ongoing digging which helps to keep things fresh!
ATVB
Good morning Krone, I hope you are well and thank you for the concern.
I am very much still here, and continuing to buy (I certainly didn't envisage such a drastic share price decline when the science was striving on through trials). I must admit I grew tired of the inane nonsense posted by several multi-ID's which was often timed to clog up the board & push decent info/science based posts down the order. The regularity with which it happened was as comical as it was sinister to be fair.
I am of course regularly digging (cannot change the habit of a lifetime!) but have eased up posting the science heavy pieces here as the board in general is more about tit-for-tat share price this, Parker that, Tim should do this, RF that.
But, it is a discussion board after all and good luck to those who wish to repeat various points with their 20/20 hindsight vision and to snipe at others.
That being said & just for the craic:
1. 03.03.2024 - Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis:
https://link.springer.com/article/10.1007/s10928-024-09901-2#Sec10
Good luck to all genuine holders, researchers and posters, I feel good news is imminent, I can feel it in my bones!
ATVB
All primed and looking good. If any well known broker has gone short recently then we may see them closing out their short position this week and buying back.
There 1ill be no problem with MAD Leggster ot only takes us up to 30% of maximum anticipated treatment dosage of 1000g per day.
Sareum had put maximum 1000mg per day on 737 and 2hilst adverse effects began to arise ( those that recieved 1200 and 1400mg ) the satisfactory treatment maximum was put at 800mg per day. Interestingly in combo therapy this daily amount can be significantly reduced in combo therapy as has been proven
It is OK l do not got info from 1980"s science data , the field of kinase inhibitors were unknown then and the science of oncology has come on leaps and bounds since.
Our compound is worth what it is worth irrespective of current Market Cap or SP..
I like many here are at a loss to the developments of 737. No indication as to who or why this information is not forthcoming. We don't own 737 but have a 27.5% financial interest, surely that should suffice to allow information as to who and what we are financially involved with.
SDC 1801 all appears fine to no surprise.
Reckon we will get an update this month on either 1801 or 737 or maybe both.
Tic tock tick tok.
Regards
Another week over, still no issues, MAD either complete or about to complete, 737 has been with its new caretakers for long enough that news could be due, and RF continuing selling low for now. Hopefully will get another news snippet or two to energise the SP over the coming weeks. I am still confident here and feel we can expect some good news in the due course of time. GLA
Agree with that SOG there's definitely a strong resurgence with Pharma and CHK1 and believe the BOD were truthful when they said interested parties where queuing up. Exciting times ahead for both SRA737 & SDC-1801 GLA
Chemotherapy has advantages in the treatment of cancer. It will kill or cause cancers to mutate.
737 works in parallel with these cancer destroying agents in that it does not allow the multiplication and repair of DNA with strand breaks ie mutated DNA. Much of this is indicated by the control of Chk1 in at the P53 checkpoint. In this sense CHK1 can only limit new cell growth and has little effect in killing cancer tumours that already exist.
What a CHK1 inhibitor does is prevent the replication or production of cancerous cells at the point of reproduction.
Hence CHK1 inhibitors need to work in conjunction with other forms of cancer killing agents or distress caused in the formulation of new cancer cells at the point of mitosis ie cell division and replication.
The most important aspect in over half of cancers is the P53 checkpoint. In this instance l have never found in any shape or form an alternative that addresses this issue
We have WEE1 PARPi and PD-1 but they are also basically ineffective as a mono treatment albeit greater efficacy in combo with the like of Chemotherapy.
CHK 1 inhibitors therefore cannot be ignored as indicated by the resurgence of CHK1 inhibitors in combination therapy. How else do you control cancer cells growing if you do not address one of the most if not the most important areas of signalling pathways if you do not address it.
Later newer approaches made, along with generated hype to induce new therapies which are supposed to address all former problems with previous inhibitors that have not given an appropriate amount of attention to maximise the the potential of inhibitors we already have.
It's a money making game for the pharma that take on to feed their greed not to dissimilar to on going wars created by the West and the US in particular to gain masses on revenue from military weapons production.
Corporate bodies as well as military establishments as well as pharmas are corrupt and that is very easily identified as well those in government play a part which is financially beneficial to them.
I will end on stressing the importance of CHK1 in the treatment of certainly difficult to treat cancers.
Prexasertib which l feel inferior to 737 in that it has issues associated with mycocardia and hence was discontinued and in addition can only be administered intravenously.
However, this did not stop Acrivon taking it on board.
Regards and adding all the time.
For sure.
Now that would be a helluva result for SAR!! π΅βπ«π΅βπ«
Interesting but choice of topic title could be better